In this Oncology Brothers podcast episode, Naval Daver, MD, MD Anderson Cancer Center, Houston, Texas, discusses treatment strategies for both therapy‑related and de novo acute myeloid leukemia (AML), focusing on cases…
Tara Lin, MD, University of Kansas Medical Center, Kansas City, Kansas, discusses how she approaches choosing induction therapy for patients with treatment-related acute myeloid leukemia, emphasizing that fitness…
With the aid of single-cell sequencing technology, researchers at Harvard Medical School have mapped the beginnings of the biological development of both zebrafish and frogs from a single-cell…
Different types of movement disorders are difficult to distinguish due to many patients experiencing similar symptoms. Stephen Stahl, MD, discusses the differences between movement disorders, how they might…
PRX002 is an investigational antibody against α-synuclein as a disease-modifying therapy that stops the misfolding of α-synuclein and/or the spread of its aggregates in the brain.
While there are not yet any standardized criteria for selecting candidates for deep brain stimulation (DBS) therapy, Kelvin L. Chou, MD, Co-Director of the STIM (Surgical Therapies Improving…
As patients begin displaying symptoms of Parkinson’s disease, it becomes increasingly difficult for them to express themselves verbally, and they may even become overwhelmed in loud social situations.…
